Content Reviewed By
Reviewed by a board-certified physician (Medical) · Reviewed by a licensed attorney specializing in mass tort litigation (Legal)
Updated March 2026
Dupixent Safety Concerns: What Patients Should Know
Medically reviewed by licensed healthcare professionals · Legally reviewed by mass tort litigation specialists · Last updated:
100+ Active Cases Reported
We are monitoring reports of cancer risk in Dupixent patients and publishing practical updates for patients and families.
Key Facts
- Dupixent is a monoclonal antibody that inhibits IL-4 and IL-13 signaling.
- FDA approval began in 2017 and expanded across multiple inflammatory conditions.
- It has been prescribed to more than 900,000 patients.
- Annual global sales have exceeded $13 billion.
- Post-marketing reports include lymphoma, skin cancer, and other solid tumors.
- No coordinated mass litigation is active yet; this remains a monitoring phase.
What We Are Monitoring
Safety reports, regulatory updates, and emerging case filings related to potential malignancy risk in Dupixent users.
Who Should Pay Closer Attention
- Patients currently using Dupixent for eczema, asthma, nasal polyps, COPD, or related indications.
- Patients diagnosed with cancer during or after Dupixent treatment.
- Families who want updates if formal litigation develops.
Register for Updates
Share your information to receive updates if new safety actions or litigation activity emerges.
Get Updates